Anti-Microbial Surface Treatment

Discussion in 'Zimmer' started by Anonymous, Jan 25, 2014 at 2:45 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest


  2. Anonymous

    Anonymous Guest

    Not sure, but one has to wonder if capitated pricing hasn't dealt a deathblow to many of these boutique technologies....
     
  3. Anonymous

    Anonymous Guest

    It's all about clinical proof. Whenever the article comes out that proves the treatment makes a difference...game changer! Problem is it may be the year 2020? By then the US health system has collapsed and can't pay for even a Rush Rod for a fracture
     
  4. Anonymous

    Anonymous Guest

    The RnD group in Austin was slashed quite a while back, including the phd guy heading that up. My understanding was that may have been defunded along with a bunch of other cool stuff.
     
  5. Anonymous

    Anonymous Guest

    The agreement was only for 18 months, and that was more than 18 months ago. They may have extended it, but the last comment is correct about the Biologic's team in TX losing the leader of that program. The other person leading it is in Hip Product Management. I wouldn't hold my breath for this product...hard to show value when antibiotic cement works well in knees, hard to get a regulatory claim (probably a long term clinical study), a surface treatment on a bearing surface (e.g. hip ball or distal knee condyle) will conflict with other design priorities. It will be difficult to upcharge a significant amount for this technology when the incidence rate of infection is 1-1.5% (albeit with great cost).